PRECIGEN, INC. Operating Income
PRECIGEN, INC. (PGEN) reported Operating Income of $22.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- PRECIGEN, INC. operating income (loss) for the quarter ending 2026-06-30 was $22.64M.
- PRECIGEN, INC. operating income (loss) for the quarter ending 2026-03-31 was -$5.99M.
- PRECIGEN, INC. operating income (loss) for the quarter ending 2025-06-30 was -$31.76M.
- PRECIGEN, INC. operating income (loss) for the quarter ending 2025-03-31 was -$22.60M.
- PRECIGEN, INC. operating income (loss) for fiscal 2025 was -$110.51M.
- PRECIGEN, INC. operating income (loss) for fiscal 2024 was -$135.03M.
- PRECIGEN, INC. operating income (loss) for fiscal 2023 was -$99.76M.
- PRECIGEN, INC. operating income (loss) for fiscal 2018 was -$505.61M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $22.64M 10-Q · filed 2026-08-04 | $16.65M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$5.99M 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | -$110.51M 10-K · filed 2026-03-25 | ||||
| 2025-06-30 | -$31.76M 10-Q · filed 2026-08-04 | -$54.36M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | -$22.60M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | -$135.03M 10-K · filed 2026-03-25 | ||||
| 2023-12-31 | -$99.76M 10-K · filed 2026-03-25 | ||||
| 2020-12-31 | -$35.17M 10-K · filed 2021-03-01 | -$58.17M derived: sum of 2 quarters · filed 2021-03-01 | -$70.00M derived: sum of 3 quarters · filed 2021-03-01 | -$86.60M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-09-30 | -$23.01M 10-K · filed 2021-03-01 | -$34.84M derived: sum of 2 quarters · filed 2021-03-01 | -$51.44M derived: sum of 3 quarters · filed 2021-03-01 | -$120.16M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-06-30 | -$11.83M 10-K · filed 2021-03-01 | -$28.43M derived: sum of 2 quarters · filed 2021-03-01 | -$97.15M derived: sum of 3 quarters · filed 2021-03-01 | -$131.86M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-03-31 | -$16.60M 10-K · filed 2021-03-01 | -$85.32M derived: sum of 2 quarters · filed 2021-03-01 | -$120.03M derived: sum of 3 quarters · filed 2021-03-01 | -$141.53M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-12-31 | -$68.72M 10-K · filed 2021-03-01 | -$77.99M 10-K · filed 2020-03-02 | -$103.43M derived: sum of 2 quarters · filed 2021-03-01 | -$124.93M derived: sum of 3 quarters · filed 2021-03-01 | -$166.79M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-09-30 | -$34.70M 10-K · filed 2021-03-01 | -$48.62M 10-Q · filed 2019-11-12 | -$56.21M derived: sum of 2 quarters · filed 2021-03-01 | -$144.73M 10-Q · filed 2019-11-12 | -$366.18M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$21.51M 10-K · filed 2021-03-01 | -$37.41M 10-Q · filed 2019-08-09 | -$96.11M 10-Q · filed 2019-08-09 | -$331.48M derived: sum of 3 quarters · filed 2021-03-01 | -$389.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$41.85M 10-K · filed 2021-03-01 | -$58.70M 10-Q · filed 2019-05-09 | -$309.97M derived: sum of 2 quarters · filed 2021-03-01 | -$368.30M derived: sum of 3 quarters · filed 2021-03-01 | -$403.11M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$268.12M 10-K · filed 2020-03-02 | -$336.88M 10-K · filed 2019-03-01 | -$326.45M derived: sum of 2 quarters · filed 2020-03-02 | -$361.26M derived: sum of 3 quarters · filed 2020-03-02 | -$505.61M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$58.33M 10-K · filed 2020-03-02 | -$66.47M 10-Q · filed 2018-11-08 | -$93.14M derived: sum of 2 quarters · filed 2020-03-02 | -$168.73M 10-Q · filed 2019-11-12 | -$161.87M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$34.81M 10-K · filed 2020-03-02 | -$49.73M 10-Q · filed 2018-08-13 | -$102.26M 10-Q · filed 2019-08-09 | -$103.54M derived: sum of 3 quarters · filed 2020-03-02 | -$148.29M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$42.24M 10-K · filed 2020-03-02 | -$48.47M 10-Q · filed 2018-05-10 | -$68.73M derived: sum of 2 quarters · filed 2020-03-02 | -$113.48M derived: sum of 3 quarters · filed 2020-03-02 | -$148.75M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$26.49M 10-K · filed 2019-03-01 | -$71.24M derived: sum of 2 quarters · filed 2019-03-01 | -$106.51M derived: sum of 3 quarters · filed 2019-03-01 | -$137.89M 10-K · filed 2019-03-01 | |
| 2017-09-30 | -$44.75M 10-K · filed 2019-03-01 | -$80.02M derived: sum of 2 quarters · filed 2019-03-01 | -$111.40M 10-Q · filed 2018-11-08 | -$143.99M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | -$35.27M 10-K · filed 2019-03-01 | -$66.65M 10-Q · filed 2018-08-13 | -$99.24M derived: sum of 3 quarters · filed 2019-03-01 | -$128.06M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | -$31.38M 10-K · filed 2019-03-01 | -$63.97M derived: sum of 2 quarters · filed 2019-03-01 | -$92.79M derived: sum of 3 quarters · filed 2019-03-01 | -$116.01M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | -$32.59M 10-K · filed 2018-03-01 | -$61.41M derived: sum of 2 quarters · filed 2018-03-01 | -$84.63M derived: sum of 3 quarters · filed 2018-03-01 | -$125.17M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$28.82M 10-K · filed 2018-03-01 | -$52.04M derived: sum of 2 quarters · filed 2018-03-01 | -$92.58M 10-Q · filed 2017-11-09 | -$126.97M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | -$23.22M 10-K · filed 2018-03-01 | -$63.76M 10-Q · filed 2017-08-09 | -$98.15M derived: sum of 3 quarters · filed 2018-03-01 | -$106.07M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | -$40.53M 10-K · filed 2018-03-01 | -$74.93M derived: sum of 2 quarters · filed 2018-03-01 | -$82.84M derived: sum of 3 quarters · filed 2018-03-01 | -$100.27M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$34.40M 10-K · filed 2017-03-01 | -$42.31M derived: sum of 2 quarters · filed 2017-03-01 | -$59.74M derived: sum of 3 quarters · filed 2017-03-01 | -$146.86M 10-K · filed 2018-03-01 | |
| 2015-09-30 | -$7.92M 10-K · filed 2017-03-01 | -$25.35M derived: sum of 2 quarters · filed 2017-03-01 | -$112.47M 10-Q · filed 2016-11-09 | -$131.43M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | -$17.43M 10-K · filed 2017-03-01 | -$104.55M 10-Q · filed 2016-08-09 | -$123.51M derived: sum of 3 quarters · filed 2017-03-01 | -$138.56M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | -$87.12M 10-K · filed 2017-03-01 | -$106.08M derived: sum of 2 quarters · filed 2017-03-01 | -$121.13M derived: sum of 3 quarters · filed 2017-03-01 | -$139.21M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | -$18.96M 10-K · filed 2016-02-29 | -$34.01M derived: sum of 2 quarters · filed 2016-02-29 | -$52.09M derived: sum of 3 quarters · filed 2016-02-29 | -$69.96M 10-K · filed 2017-03-01 | |
| 2014-09-30 | -$15.05M 10-K · filed 2016-02-29 | -$33.13M derived: sum of 2 quarters · filed 2016-02-29 | -$51.00M 10-Q · filed 2015-11-09 | -$68.73M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | -$18.08M 10-K · filed 2016-02-29 | -$35.95M 10-Q · filed 2015-08-10 | -$53.68M derived: sum of 3 quarters · filed 2016-02-29 | -$65.72M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | -$17.87M 10-K · filed 2016-02-29 | -$35.60M derived: sum of 2 quarters · filed 2016-02-29 | -$47.63M derived: sum of 3 quarters · filed 2016-02-29 | -$61.89M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | -$17.73M 10-K · filed 2015-03-02 | -$29.76M derived: sum of 2 quarters · filed 2015-03-02 | -$44.02M derived: sum of 3 quarters · filed 2015-03-02 | -$58.02M 10-K · filed 2016-02-29 | |
| 2013-09-30 | -$12.04M 10-K · filed 2015-03-02 | -$26.29M derived: sum of 2 quarters · filed 2015-03-02 | -$40.30M 10-Q · filed 2014-11-13 | -$52.60M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | -$14.25M 10-K · filed 2015-03-02 | -$28.26M 10-Q · filed 2014-08-14 | -$40.56M derived: sum of 3 quarters · filed 2015-03-02 | -$57.05M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | -$14.01M 10-K · filed 2015-03-02 | -$26.31M derived: sum of 2 quarters · filed 2015-03-02 | -$42.79M derived: sum of 3 quarters · filed 2015-03-02 | -$64.04M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | -$12.30M 10-K · filed 2014-03-31 | -$28.79M derived: sum of 2 quarters · filed 2014-03-31 | -$50.04M derived: sum of 3 quarters · filed 2014-03-31 | -$75.16M 10-K · filed 2015-03-02 | |
| 2012-09-30 | -$16.48M 10-K · filed 2014-03-31 | -$37.73M derived: sum of 2 quarters · filed 2014-03-31 | -$62.85M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$21.25M 10-K · filed 2014-03-31 | -$46.37M 10-Q/A · filed 2013-10-21 | |||
| 2012-03-31 | -$25.12M 10-K · filed 2014-03-31 | ||||
| 2011-12-31 | -$82.43M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |